A 28-year-old patient presented to us with multifocal coarse raised epithelial lesions in the left eye associated with pain watering redness and blurred vision with a visual acuity of 20/40 in the left eye. The patient had been managed elsewhere with a course of topical moxifloxacin eye-drops four times a day and topical steroids (prednisolone acetate) 1% three times a day for 2 weeks without any resolution, which was stopped 2 days ago prior to presentation at our centre. Gram stain was negative for bacteria as well as microsporidial spores. 10% KOH was negative for fungal hyphae. Based on strong clinical signs of corneal microsporidiosis, in spite of the negative microbiology smear, the patient was started on voriconazole eye-drops five times a day. The lesions started resolving in 5 days and completely healed after 17 days of therapy. No relevant history pertaining to exposure of contaminated water, swimming or history of trauma could be elicited.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366807 | PMC |
http://dx.doi.org/10.1136/bcr-2018-228407 | DOI Listing |
Surg Infect (Larchmt)
January 2025
Division of Trauma, Surgical Critical Care, Burns, and Acute Care Surgery, Department of Surgery, UC San Diego, San Diego, California, USA.
Cholecystectomy is the recommended treatment for acute cholecystitis in pregnancy, leading to fewer pregnancy-related complications than non-operative management. However, past research demonstrated high rates of non-operative management despite these recommendations. Rates of cholecystostomy tube usage and outcomes in pregnancy are not well described.
View Article and Find Full Text PDFBackground: Continuous anticoagulation based on the CHA2DS2-VASc score is recommended to prevent embolism caused by atrial fibrillation (AF), but it does not consider AF episodes. The Apple Watch's continuous heart rhythm monitoring and fast-acting direct oral anticoagulants (DOACs) could enable precise, episode-tailored anticoagulation, reducing bleeding risks while preventing stroke. This study evaluates Apple Watch-guided personalized anticoagulation therapy, adjusting DOAC usage based on real-time AF detection.
View Article and Find Full Text PDFOsteoarthr Cartil Open
March 2025
OrthoSport Victoria, Level 5, 89 Bridge Rd, Richmond, Victoria, Australia.
Objective: To compare urinary C-terminal cross-linked telopeptide of type II collagen (u-CTX-II) concentrations and trends as measured by two different commercially available enzyme-linked immunosorbent assays (ELISA) in a cohort of patients in the first year following anterior cruciate ligament (ACL) reconstruction.
Design: 22 ACL-injured patients undergoing reconstructive surgery (mean age 25.2 (SD 8.
J Spine Surg
December 2024
Department of Orthopedic Surgery, Chung Shan Hospital, Taipei, Taiwan.
Background: Prone lateral spinal surgery for simultaneous lateral and posterior approaches has recently been proposed to facilitate surgical room efficiency. The purpose of this study is to evaluate the feasibility and outcomes of minimally invasive prone lateral spinal surgery using a rotatable radiolucent Jackson table.
Methods: From July 2021 to June 2023, a consecutive series of patients who received minimally invasive prone lateral spinal surgery for various etiologies by the same surgical team were reviewed.
Surg Open Sci
January 2025
Division of Breast Cancer Surgery, Department of Surgery, National Cancer Institute, Bangkok, Thailand.
Background: Breast cancer is the most common cancer among women. In response to the need to hospital stays and minimize waiting time for surgery, particularly during the COVID-19 pandemic, the National Cancer Institute developed the One Day Surgery with Breast cancer Home Recovery program (ODS BHR NCI). The aim of study is to assess the success rate of breast cancer surgeries conducted through this program and to evaluate the incidence of complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!